GLPBio

Cerulenin

Catalog No.: GC14025Purity:>98.00%Synonyms: Helicocerin, NSC 116069
La cerulenina, un potente inhibidor natural de la sintasa de Ácidos grasos (FASN), es un epÓxido producido por el hongo Cephalosporium caeruleus.

Los productos son exclusivamente para uso en investigación. No aptos para uso humano. No vendemos a pacientes.


Cerulenin
Cas No.: 17397-89-6
5mgIn Stock
$164.00
1
10mgIn Stock
$312.00
1
50mgIn Stock
$1,225.00
1

Citas (Citations)

Actualmente no hay citas disponibles para este producto. A continuación se muestran publicaciones seleccionadas que citan productos GlpBio.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Descripción (Description)

Cerulenin, the best known natural inhibitor of fatty acid synthase (FAS), is an epoxide produced by the fungus Cephalosporium caeruleus.
Cerulenin covalently binds to the catalytic site of FAS and disrupts the condensation reaction of acetyl-COA and malonyl-COA, inhibiting the biosynthesis of fatty acids and sterols in yeast. The Flavonoids quercetin and trans-Chalcone are effective against T. rubrum, with MICs of 125 and 7.5 μg/mL for the wild-type strain (MYA3108) and of 63 and 1.9 μg/mL for the ABC transporter mutant strain (ΔTruMDR2), respectively. The MICs of the Fluconazole and Cerulenin controls are 63 and 125 μg/mL for the wild-type strain and 30 and 15 μg/mL for the mutant strain, respectively[1]. To explore the underlying mechanism of Steroidogenic acute regulatory protein (StAR)’s protective effect on endothelial dysfunction model, the inhibitor of fatty acid synthase and HMG-CoA reductase, Cerulenin ( 5 μg/mL) and Lovastatin, are used before palmitic acid (PA) added. The mRNA expression of IL-1β, TNFα, VCAM-1 and IL-6 are reduced while NO production is recovered with inhibitor treatment[2].
Cerulenin treatment of ob/ob mice has obvious effects on body weight. With 2 days of treatment, body weight in treated mice is decreased compared to a 5.7% weight gain in the controls. With prolonged (7 days) treatment, no body weight loss is observed, but body weight gain is slowed. In all groups, 60 mg/kg of Cerulenin is more effective than 30 mg/kg in inhibiting weight gain. If given daily or every other day, ATP content are increased 58.1% and 61.5% respectively by 7-day treatment of 60 mg/kg Cerulenin. Significant ATP elevation is also observed with only 2 days of treatment with 60 mg/kg Cerulenin. In contrast, 30 mg/kg Cerulenin, given either 2 or 7 days, does not show any significant effect on cellular ATP content[3].
Reference:
[1]. Bitencourt TA, et al. Trans-chalcone and quercetin down-regulate fatty acid synthase gene expression and reduce ergosterol content in the human pathogenic dermatophyte Trichophyton rubrum. BMC Complement Altern Med. 2013 Sep 17;13:229.
[2]. Tian D, et al. Overexpression of steroidogenic acute regulatory protein in rat aortic endothelial cells attenuates palmitic acid-induced inflammation and reduction in nitric oxide bioavailability. Cardiovasc Diabetol. 2012 Nov 21;11:144.
[3]. Cheng G, et al. Cerulenin blockade of fatty acid synthase reverses hepatic steatosis in ob/ob mice. PLoS One. 2013 Sep 27;8(9):e75980.

Protocolo (Protocol)

Cell experiment:

Rat aortic endothelial cells (RAECs) are isolated and cultured with minor modifications. Briefly, segments of thoracic aorta are excised from male Wistar rats (150-180 g) and immediately placed in cold PBS containing 100 U/mL Penicillin and 100 mg/mL Streptomycin. The aorta is cut into 1 millimeter wide rings after the periadventitial fat is removed. Following transferred to a T-25 cm2 flasks, the rings are cultured in Medium 199 containing 20% fetal bovine serum, 2.5 ng/mL basic fibroblast growth factors, 100U/mL Penicillin and 100 mg/mL Streptomycin. The aorta rings are placed at 37°C in a humidified atmosphere with 5% CO2 for 72-80 h without movement. All pieces of aorta rings are removed when cells migrated. Its microvascular cytological characteristics are demonstrated by CD31 and vWF staining. In experiments involving PA treatment, M199 medium supplemented with 1% bovine serum albumin is used. All experiments are performed with RAECs up to passage 4. In the experiments with inhibitor, 5 μg/mL Cerulenin (in ethonal), or 5 μM Lovastatin (in DMSO), or 3.3 μg/mL Cerulenin plus 3.3 μM Lovastatin is added in culture media 24 hours prior to PA treatment. The same volume of solvents is added at the same time as control[2].

Animal experiment:

mice[3]Cerulenin is given to 6-8 week old male ob/ob mice in RPMI medium containing 20% DMSO intraperitoneally (i.p.). Controls are injected similarly with vehicle alone. The experimental groups (4 mice each) are as follows: A: 60 mg/kg/day Cerulenin, injected daily for 7 days; B: 60 mg/kg every other day for 7 days; C: 30 mg/kg/day for 7 days; D: 30 mg/kg every other day for 7 days; E: vehicle, daily for 7 days; F: 60 mg/kg/day Cerulenin for 2 days; G: 30 mg/kg/day Cerulenin for 2 days; H: vehicle, daily for 2 days; I: control. All animals are sacrificed on the same day under anesthesia. Blood is collected by portal vein puncture. Liver samples are snap-frozen in liquid N2 and stored at -80°C until analysis, or paraformaldehyde-fixed for histological analysis.

References:

[1]. Bitencourt TA, et al. Trans-chalcone and quercetin down-regulate fatty acid synthase gene expression and reduce ergosterol content in the human pathogenic dermatophyte Trichophyton rubrum. BMC Complement Altern Med. 2013 Sep 17;13:229.
[2]. Tian D, et al. Overexpression of steroidogenic acute regulatory protein in rat aortic endothelial cells attenuates palmitic acid-induced inflammation and reduction in nitric oxide bioavailability. Cardiovasc Diabetol. 2012 Nov 21;11:144.
[3]. Cheng G, et al. Cerulenin blockade of fatty acid synthase reverses hepatic steatosis in ob/ob mice. PLoS One. 2013 Sep 27;8(9):e75980.

Documentos del producto (Product Documents)

Purity:>98.00%Appearance:A solid

Propiedades químicas (Chemical Properties)

N.º CAS
17397-89-6
Sinónimos
Helicocerin, NSC 116069
Nombre químico
2R,3S-epoxy-4-oxo-7,10-dodecadienamide
SMILES
C/C=C/C/C=C/CCC([C@@H]1[C@H](C(N)=O)O1)=O
Fórmula molecular
C12H17NO3
Peso molecular
223.3
Solubilidad
DMF: 30 mg/ml; DMF:PBS (pH 7.2)(1:6): .2 mg/ml; DMSO: 25 mg/ml; Ethanol: 20 mg/ml
Almacenamiento
Store at -20°C
Consejos generales
Seleccione un disolvente adecuado según los datos de solubilidad del producto. Una vez preparada, divida la solución madre en alícuotas para evitar ciclos repetidos de congelación y descongelación.
Utilice las soluciones madre en un plazo de 6 meses si se conservan a -80°C, o de 1 mes si se conservan a -20°C.
Para mejorar la solubilidad, caliente el tubo a 37°C y soníquelo durante un periodo adecuado.
Condiciones de envío
Las muestras de evaluación se envían con acumuladores de frío. Los demás tamaños se envían a temperatura ambiente o, previa solicitud, con acumuladores de frío.

Calculadoras (Calculators)Molaridad / Dilución / Peso molecular / Conversión de unidades / Formulación in vivo / Solubilidad

g/mol

Reviews

Review for Cerulenin

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%